NO20044530L - Fremgangsmate for behandling av kognitive forstyrrelser - Google Patents

Fremgangsmate for behandling av kognitive forstyrrelser

Info

Publication number
NO20044530L
NO20044530L NO20044530A NO20044530A NO20044530L NO 20044530 L NO20044530 L NO 20044530L NO 20044530 A NO20044530 A NO 20044530A NO 20044530 A NO20044530 A NO 20044530A NO 20044530 L NO20044530 L NO 20044530L
Authority
NO
Norway
Prior art keywords
cognitive disorders
procedure
treatment
phenylcanamoyleseroline
alzheimer
Prior art date
Application number
NO20044530A
Other languages
English (en)
Inventor
Nigel Greig
Gosse Bruinsma
Original Assignee
Us Gov Health & Human Serv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv filed Critical Us Gov Health & Human Serv
Publication of NO20044530L publication Critical patent/NO20044530L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Peparater og fremgangsmåter for behandling av sykdommer som skyldes kognitive forstyrrelser, f eks. Alzheimers sykdom, med forbindelsen (+)9-N-fenylkanbamoyleserolin som aktiv bestanddel.
NO20044530A 2002-03-22 2004-10-21 Fremgangsmate for behandling av kognitive forstyrrelser NO20044530L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36706802P 2002-03-22 2002-03-22
US10/386,915 US20040024043A1 (en) 2002-03-22 2003-03-12 Method for treating cognitive disorders
PCT/US2003/008407 WO2003082270A1 (en) 2002-03-22 2003-03-18 Method for treating cognitive disorders

Publications (1)

Publication Number Publication Date
NO20044530L true NO20044530L (no) 2004-10-21

Family

ID=28678179

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20044530A NO20044530L (no) 2002-03-22 2004-10-21 Fremgangsmate for behandling av kognitive forstyrrelser

Country Status (16)

Country Link
US (1) US20040024043A1 (no)
EP (1) EP1490057A4 (no)
JP (1) JP2005526806A (no)
KR (1) KR100609381B1 (no)
CN (1) CN1642541A (no)
AU (1) AU2003230683B2 (no)
BR (1) BR0306855A (no)
CA (1) CA2476923A1 (no)
HR (1) HRP20040992A2 (no)
IL (1) IL163993A0 (no)
MX (1) MXPA04009136A (no)
NO (1) NO20044530L (no)
NZ (1) NZ534726A (no)
PL (1) PL372315A1 (no)
RU (1) RU2280449C2 (no)
WO (1) WO2003082270A1 (no)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004292966A1 (en) * 2003-11-21 2005-06-09 Memory Pharmaceutical Corporation Compositions and methods of treatment using L-type calcium channel blockers and cholinesterase inhibitors
EP1737445A4 (en) 2004-03-19 2007-05-09 Axonyx Inc METHOD FOR TREATING DOWN SYNDROME
JP2007529556A (ja) * 2004-03-19 2007-10-25 アクソニクス インコーポレイテッド 認知障害の処置に有用なアセチルコリンエステラーゼ阻害剤およびｎ−メチル−ｄ−アスパラギン酸拮抗剤
US9095573B2 (en) * 2005-08-01 2015-08-04 University Of Central Florida Research Foundation, Inc. Method of biasing implanted human neural stem cells away from differentiation into glial cells by (+)phenserine to modulate the concentration of soluble βAPP in tissue or CSF
RU2327480C1 (ru) 2007-05-23 2008-06-27 Виктор Иванович Рощин Активный ингредиент лекарственного средства, лекарственное средство, фармацевтическая композиция и способ лечения больных с дементным синдромом
US9006283B2 (en) 2007-07-12 2015-04-14 Acumen Pharmaceuticals, Inc. Methods of modifying amyloid β oligomers using non-peptidic compounds
US8962677B2 (en) 2007-07-12 2015-02-24 Acumen Pharmaceuticals, Inc. Methods of restoring cognitive ability using non-peptidic compounds
US20120225922A1 (en) * 2011-03-04 2012-09-06 Qr Pharma Effective Amounts of (3aR)-1,3a,8-Trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo [2,3-b]indol-5-yl Phenylcarbamate and Methods of Treating or Preventing Neurodegeneration
DK3334425T3 (da) 2015-08-14 2021-02-22 Qr Pharma Methods of treatment or prevention of acute brain or nerve injuries
US10864192B2 (en) 2016-01-15 2020-12-15 Aristea Translational Medicine Corporation Compositions and methods for inhibiting brain trauma-induced neurodegeneration and related conditions
US10111860B1 (en) 2016-01-15 2018-10-30 Aristea Translational Medicine Corporation Compositions and methods for treating concussion
US10751340B2 (en) 2016-06-06 2020-08-25 University Of Central Florida Research Foundation, Inc. Combination therapy to improve brain function or promote neurogenesis for treating neurodegenerative conditions
WO2018217892A1 (en) 2017-05-24 2018-11-29 Qr Pharma, Inc. Prevention or treatment of disease states due to metal dis-homeostasis via administration of posiphen to healthy or sick humans
WO2024263878A2 (en) * 2023-06-21 2024-12-26 Annovis Bio, Inc. Solid forms of posiphen d-tartrate
WO2025017530A1 (en) * 2023-07-19 2025-01-23 Assia Chemical Industries Ltd. Solid state forms of buntanetap and process for preparation thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5409948A (en) * 1992-11-23 1995-04-25 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method for treating cognitive disorders with phenserine
RU2123858C1 (ru) * 1994-09-13 1998-12-27 Белокоскова Светлана Георгиевна Способ лечения афазии
RU2106864C1 (ru) * 1995-10-23 1998-03-20 Николай Серафимович Зефиров Средство для лечения болезни альцгеймера
ATE406371T1 (de) * 2000-11-02 2008-09-15 Us Gov Health & Human Serv Wirkstoffe für die verminderung von amyloid precursor protein und die behandlung von schwachsinn, und deren verfahren der verwendung

Also Published As

Publication number Publication date
MXPA04009136A (es) 2004-12-07
KR100609381B1 (ko) 2006-08-08
IL163993A0 (en) 2005-12-18
WO2003082270A1 (en) 2003-10-09
EP1490057A4 (en) 2007-07-11
AU2003230683B2 (en) 2006-04-06
HRP20040992A2 (en) 2005-02-28
JP2005526806A (ja) 2005-09-08
CA2476923A1 (en) 2003-10-09
AU2003230683A1 (en) 2003-10-13
EP1490057A1 (en) 2004-12-29
US20040024043A1 (en) 2004-02-05
NZ534726A (en) 2006-06-30
CN1642541A (zh) 2005-07-20
RU2004131214A (ru) 2005-04-10
RU2280449C2 (ru) 2006-07-27
BR0306855A (pt) 2005-04-05
KR20040101319A (ko) 2004-12-02
PL372315A1 (en) 2005-07-11

Similar Documents

Publication Publication Date Title
GB0318447D0 (en) Therapeutic agents
GB0225475D0 (en) Therapeutic agents
NO20035474D0 (no) Prodrugs av GABA-analoger, sammensetninger og anvendelse derav
EA200900802A1 (ru) Способы и композиции для лечения амилоидных заболеваний
EA200600078A1 (ru) Способы и композиции для лечения амилоидных заболеваний
NO20053263L (no) Hydroksyetylaminderivater for behandling av Alzheimers sykdom.
DE60219917D1 (de) Naphtoquinone derivate als inhibitoren von tau aggregation zur behandlung von alzheimer's und verbundenen neurodegenerativen erkrankungen
NO20044530L (no) Fremgangsmate for behandling av kognitive forstyrrelser
NO20034056D0 (no) Proliferative sykdommer
DE50310516D1 (de) Fredericamycin-derivate
MY144483A (en) 1,2,3,4-tetrasubstituted indole for the treatment of respiratory diseases
DE60126980D1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
BR0116370A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento de uma doença ou condição mediada por hppar em um paciente.
ATE357438T1 (de) 1,2,4-triaminobenzolderivate zur behandlung von erkrankungen des zentralnervensystems
BRPI0407662A (pt) derivados do ácido 1-fenilalcanocarboxìlico para o tratamento de doenças neurodegenerativas
BR0316723A (pt) Derivados de anilinopirazol úteis para o tratamento de diabetes
DE60315479D1 (de) Pyrimidinamid derivate und deren verwendung
NO20060020L (no) 3-fluorpiperidiner som NMDA/NR2B-antagonister
CY1109666T1 (el) Μεθοδος θεραπειας διαταραχων ξηροφθαλμιας και ραγοειδιτιδας
MY139368A (en) Novel cyclohexyl sulphones
NO20052267L (no) Forbindelser, Preparater og Metoder
NO20055450L (no) Kombinasjon av et analeptisk modafinili og en antidepressiv forbindelse for behandling av depresjon
CY1106155T1 (el) Χρηση παραγωγων 3-βενζολοφαινυλοξικων οξεων για την αντιμετωπιση διαταραχων του αμφιβληστροειδους
BR0314540A (pt) Métodos para o tratamento de neurodegeneração
ATE482217T1 (de) Dithiolopyrrolon-derivate zur behandlung von proliferativen störungen

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application